JP2023536264A5 - - Google Patents
Info
- Publication number
- JP2023536264A5 JP2023536264A5 JP2023506226A JP2023506226A JP2023536264A5 JP 2023536264 A5 JP2023536264 A5 JP 2023536264A5 JP 2023506226 A JP2023506226 A JP 2023506226A JP 2023506226 A JP2023506226 A JP 2023506226A JP 2023536264 A5 JP2023536264 A5 JP 2023536264A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- approximately
- combination according
- compound
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063059601P | 2020-07-31 | 2020-07-31 | |
| US63/059,601 | 2020-07-31 | ||
| US202063113556P | 2020-11-13 | 2020-11-13 | |
| US63/113,556 | 2020-11-13 | ||
| US202163148921P | 2021-02-12 | 2021-02-12 | |
| US63/148,921 | 2021-02-12 | ||
| PCT/US2021/043699 WO2022026706A1 (en) | 2020-07-31 | 2021-07-29 | Combinations for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023536264A JP2023536264A (ja) | 2023-08-24 |
| JP2023536264A5 true JP2023536264A5 (enExample) | 2024-08-05 |
| JP7847576B2 JP7847576B2 (ja) | 2026-04-17 |
Family
ID=77431400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023506226A Active JP7847576B2 (ja) | 2020-07-31 | 2021-07-29 | がんの治療のための組み合わせ |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230301979A1 (enExample) |
| EP (1) | EP4188376A1 (enExample) |
| JP (1) | JP7847576B2 (enExample) |
| KR (1) | KR20230059792A (enExample) |
| CN (1) | CN116437954A (enExample) |
| AU (1) | AU2021318134A1 (enExample) |
| BR (1) | BR112023001792A2 (enExample) |
| CA (1) | CA3186517A1 (enExample) |
| CL (1) | CL2023000289A1 (enExample) |
| CO (1) | CO2023001561A2 (enExample) |
| CR (1) | CR20230052A (enExample) |
| IL (1) | IL300151A (enExample) |
| MX (1) | MX2023001298A (enExample) |
| PE (1) | PE20231369A1 (enExample) |
| PH (1) | PH12023550160A1 (enExample) |
| TW (1) | TW202220654A (enExample) |
| WO (1) | WO2022026706A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117402114A (zh) * | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| CN115210252A (zh) | 2020-02-04 | 2022-10-18 | 西雅图儿童医院（Dba西雅图儿童研究所） | 抗二硝基苯酚的嵌合抗原受体 |
| JP2023523142A (ja) * | 2020-04-29 | 2023-06-02 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 精子症状を有する個体における妊孕性向上食事推奨案を提供するためのシステム及び方法 |
| EP4143851A1 (en) * | 2020-04-29 | 2023-03-08 | Société des Produits Nestlé S.A. | System and method for providing fertility enhancing dietary recommendations in individuals with low testosterone |
| KR20250029015A (ko) * | 2022-03-07 | 2025-03-04 | 사노피-아벤티스 유.에스. 엘엘씨 | 다발성 골수종의 치료를 위한, 다른 제제와 조합된 이사툭시맙의 용도 |
| CA3255739A1 (en) * | 2022-04-08 | 2023-10-12 | Global Cancer Technology, Inc. | METHODS AND PRODUCTS FOR SCREENING AND TREATMENT OF GLIOBLASTOMA MULTIFORME AND OTHER CANCERS, INCLUDING BREAST CANCERS, USING A COMBINATION OF PI3KINASE INHIBITORS WITH CHECKPOINT INHIBITORS |
| EP4604956A1 (en) * | 2022-10-19 | 2025-08-27 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Therapeutic methods with target-linked small molecules and anti-target car t cells |
| EP4665766A2 (en) * | 2023-02-13 | 2025-12-24 | LAVA Therapeutics N.V. | Combination therapy comprising multispecific gamma delta tcr antibodies |
| EP4450972A1 (en) * | 2023-04-21 | 2024-10-23 | Fundación Instituto de Investigación Sanitaria de Santiago de Compostela | In vitro method for predicting cancer patient response to pd-1 and/or pd-l1 inhibitors |
| CN117285533B (zh) * | 2023-11-24 | 2024-01-30 | 四川省医学科学院·四川省人民医院 | CD47/SIRPα小分子抑制剂及其应用和抗肿瘤药物组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| WO2018064191A1 (en) * | 2016-09-27 | 2018-04-05 | The Usa Of America, As Represented By The Secretary, Department Of Health & Human Services | Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)-phenyl)-n'(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| US11198731B2 (en) * | 2017-01-20 | 2021-12-14 | Exelixis, Inc. | Combinations of cabozantinib and atezolizumab to treat cancer |
| CN117402114A (zh) * | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| KR102828472B1 (ko) | 2018-12-13 | 2025-07-03 | 엑셀리시스, 인코포레이티드 | 키나아제 억제제의 결정질 형태 및 염 형태 |
-
2021
- 2021-07-29 IL IL300151A patent/IL300151A/en unknown
- 2021-07-29 AU AU2021318134A patent/AU2021318134A1/en active Pending
- 2021-07-29 EP EP21758525.6A patent/EP4188376A1/en active Pending
- 2021-07-29 PH PH1/2023/550160A patent/PH12023550160A1/en unknown
- 2021-07-29 CR CR20230052A patent/CR20230052A/es unknown
- 2021-07-29 CA CA3186517A patent/CA3186517A1/en active Pending
- 2021-07-29 CN CN202180065378.8A patent/CN116437954A/zh active Pending
- 2021-07-29 MX MX2023001298A patent/MX2023001298A/es unknown
- 2021-07-29 WO PCT/US2021/043699 patent/WO2022026706A1/en not_active Ceased
- 2021-07-29 PE PE2023000162A patent/PE20231369A1/es unknown
- 2021-07-29 BR BR112023001792A patent/BR112023001792A2/pt unknown
- 2021-07-29 KR KR1020237006875A patent/KR20230059792A/ko active Pending
- 2021-07-29 JP JP2023506226A patent/JP7847576B2/ja active Active
- 2021-07-29 US US18/018,805 patent/US20230301979A1/en active Pending
- 2021-07-30 TW TW110128221A patent/TW202220654A/zh unknown
-
2023
- 2023-01-30 CL CL2023000289A patent/CL2023000289A1/es unknown
- 2023-02-14 CO CONC2023/0001561A patent/CO2023001561A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023536264A5 (enExample) | ||
| JP7122357B2 (ja) | がんの治療のための方法、組成物、及びキット | |
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP6805336B2 (ja) | 薬学的組み合わせ | |
| JP2024095791A (ja) | 癌の処置のためのアパチニブを用いる併用療法 | |
| US12403154B2 (en) | Administration of sting agonist and checkpoint inhibitors | |
| US20200281923A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| JP2019525948A5 (enExample) | ||
| JP2020506945A (ja) | がんの治療のための方法、組成物及びキット | |
| CN118401259A (zh) | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 | |
| WO2021244551A1 (zh) | c-Met激酶抑制剂和抗PD-L1抗体的联用药物组合物 | |
| JP2024540417A5 (enExample) | ||
| TW202233206A (zh) | Ｓｔｉｎｇ促效劑、檢查點抑制劑及輻射之投與 | |
| CN113473989B (zh) | Sumo活化酶抑制剂和检查点抑制剂的施用 | |
| JP2022507686A (ja) | 薬学的方法 | |
| WO2021180027A1 (zh) | 抗pd-1抗体和多受体酪氨酸激酶抑制剂的药物组合及其使用方法 | |
| CN116490244A (zh) | Sting激动剂、检查点抑制剂和辐射的施用 | |
| AU2024262533A1 (en) | Drug for treating locally advanced unresectable or metastatic colorectal cancer and use thereof | |
| CN118159538A (zh) | 含met受体酪氨酸激酶抑制剂的药物组合及应用 | |
| WO2025228596A1 (en) | Combination of pm14 and a topoisomerase i inhibitor in the treatment of cancer | |
| WO2025232801A1 (zh) | 抗FRα抗体药物偶联物和PD-1拮抗剂在治疗肿瘤中的应用 | |
| TW202432586A (zh) | 用於治療癌症之組合療法 | |
| TW202304450A (zh) | 以雄性素受體拮抗劑進行的轉移性去勢抗性前列腺癌患者之治療 | |
| CN116265030A (zh) | 包含酪氨酸激酶抑制剂德立替尼的药物组合 | |
| WO2026077321A1 (zh) | 抗her2抗体药物偶联物和免疫检查点抑制剂的药物组合 |